Health & Fitness
Health and Fitness
Health and Fitness
Thu, December 18, 2008
Zacks Analyst Interview Highlights: St. Jude Medical, Baxter International, Becton Dickinson, Bostom Scientific and CR Bard
CHICAGO--([ BUSINESS WIRE ])--Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Christopher Titus, who discusses St. Jude Medical (NYSE: STJ), Baxter International (NYSE: BAX), Becton Dickinson (NYSE: BDX), Boston Scientific (NYSE: BSX) and CR Bard (NYSE: BCR).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: [ http://at.zacks.com/?id=2678 ].
Medical device stocks should provide investors with opportunities for solid, lower-risk returns over the coming six to twelve months. Companies providing life-sustaining products should remain insulated from the current economic crisis, as target patients are unable to forego these procedures. The recent slide in the market has left many strong companies looking very attractive.
During the third quarter, many of these names performed well on a financial basis. Areas within our coverage that should perform well include cardiovascular devices and surgical equipment, blood related products, and associated consumables. As a result of the solid performance and outlook, we upgraded five stocks to BUY. These names include St. Jude Medical (NYSE: STJ), Baxter International (NYSE: BAX), Becton Dickinson (NYSE: BDX), Boston Scientific (NYSE: BSX) and CR Bard (NYSE: BCR).
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks Profit from the Pros e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting [ http://at.zacks.com/?id=2679 ].
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at [ http://at.zacks.com/?id=4581 ].
Visit [ http://www.zacks.com/performance ] for information about the performance numbers displayed in this press release.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
